News

IL-13 is an immune regulatory cytokine and IL-13Ra2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. ICT-107 is the

The partnership will leverage DBV’s skin patch, Viaskin, and Stallergenes’ expertise in respiratory allergies in developing immunotherapy treatments for respiratory allergies. DBV Technologies chairman and CEO Dr. Pierre-Henri

The two-stage trial is performed as a double masking test at each stage. It will include around 120 study subjects in the first and second stage studies. R-Tech

The novel anti-IL-6 monoclonal antibody RYI-008 is believed to have a potential to define new paradigm in the treatment of autoimmune diseases and cancer. RuiYi president and CEO

Paradigm 2 is a multi-centre, blinded study designed to assess the safety and efficacy of the glycopegylated recombinant factor IX as on-demand or prophylactic treatment against haemophilia B.

The app enables to share large data sets in Illumina’s BaseSpace cloud, where they can easily be reviewed and included in Elsevier’s open access journal, Genomics Data. The

As per the terms of the agreement, BASF will use Dyadic’s patented and proprietary C1 platform technology to develop, manufacture, distribute and sell industrial enzymes in certain fields

As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn’s disease, which is designed to facilitate rapid progression into Phase 3. AbbVie

Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that is used as a therapeutic drug to treat advanced chronic heart failure (CHF). As per the terms